Health News

Glenmark launches AKYNZEO IV for preventing chemotherapy induced nausea

EXCLUSIVE

AKYNZEO IV is a fixed dose combination of fosnetupitant (235 mg) and palonosetron (0.25 mg), and is available as a ready-to-dilute IV injection. It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV.




Source link

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button